Antibiotics - Therapeutic Spectrum and Limitations
- 1st Edition - July 13, 2023
- Imprint: Academic Press
- Editors: Amal Kumar Dhara, Amit Kumar Nayak, Debprasad Chattopadhyay
- Language: English
- Paperback ISBN:9 7 8 - 0 - 3 2 3 - 9 5 3 8 8 - 7
- eBook ISBN:9 7 8 - 0 - 3 2 3 - 9 5 7 8 6 - 1
Antibiotics: Therapeutic Spectrum and Limitations provides up-to-date information on managing microbial infections, the development and types of antibiotics, the rationale… Read more
Purchase options
Institutional subscription on ScienceDirect
Request a sales quoteAntibiotics: Therapeutic Spectrum and Limitations provides up-to-date information on managing microbial infections, the development and types of antibiotics, the rationale for utilizing antibiotics, toxicity considerations, and the control of antibiotic resistance in one single resource. This book also aims to provide comprehensive insights and current trends on antibiotic therapies to treat microbial infections, their mechanisms of action, and the role of modern drug delivery in improving their efficacy. Written by leading experts from around the globe, the chapters in the book covers important aspects of microbial infections including hospital acquired infections and community acquired infections and adult sepsis, examines the various types of antibiotics with different mechanisms and therapeutic uses, the global challenge of antibiotic resistance, and clinical trials, regulatory considerations, and market overview of antibiotics. Furthermore, the chapters include updated literature reviews of the relevant key topics, high-quality illustrations, chemical structures, flowcharts, and well-organized tables, all of which enable better understanding by the readers.
- Provides in-depth and updated information and analyses on microbial infections, antibiotics and therapeutics, the consequences of antibiotic resistance, and the role of modern drug delivery in improving efficacy
- Discusses different types of antibiotics and their mechanisms as well as traditional medicine, herbal drugs, and postbiotics in the treatment and prevention of microbial infections and management of antibiotic resistance
- Contributed by global leaders and experts from academia, industry, research institutes, and regulatory agencies
Postgraduate students, doctoral and postdoctoral research fellows, academicians, pharmaceutical formulators, scientists, researchers, and regulatory scientists of Medical, Pharmaceutical, Biotechnology, Biomedical, Biology, Microbiology, can serve as a collection of knowledge or reference guide in a range of courses related to Medical Sciences (M.B.B.S., M.D., Ph.D.), Pharmacy (M. Pharm, Ph.D., Pharm D), Biotechnology (M. Sc., M. Tech, Ph.D.), Biomedical Sciences (M. Sc, M.Tech, Ph.D.), and Microbiology (M. Sc., M. Tech, Ph.D.), where academician, students, researchers, and scientists are taught on microbial infections and antibiotics for the management of various disease conditions
- Cover
- Title page
- Table of Contents
- Copyright
- Contributors
- Preface
- Section I: Introduction
- Chapter 1: Introduction to antibiotic therapy
- Abstract
- 1: Introduction
- 2: Bacterial infection
- 3: Antibiotic era
- 4: Challenges in the development of antibiotics
- 5: Classes of antibiotics and their therapeutic spectrum
- 6: β-Lactam antibiotics
- 7: Aminoglycoside antibiotics
- 8: Chloramphenicol and tetracyclines
- 9: Macrolide antibiotics
- 10: Lincosamide and glycopeptide antibiotics
- 11: Polypeptide antibiotics
- 12: Antifungal antibiotics
- 13: Antitubercular antibiotics
- 14: Toxicity of antibiotics
- 15: Antimicrobial resistance
- 16: Prospect of probiotics and natural products
- 17: Conclusion
- References
- Section II: Microbial infection and antibiotics development
- Chapter 2: Bacterial infections: Types and pathophysiology
- Abstract
- 1: Infection: An overview
- 2: Bacterial infections and mechanism of pathogenesis
- 3: Types of bacterial infections and pathophysiology
- 4: Conclusions
- References
- Chapter 3: Antibiotics role in past and present: A challenge to find new possibilites in development
- Abstract
- 1: Introduction
- 2: Mechanisms of resistance to antibiotics (Fig. 4)
- 3: Antimicrobial chemotherapy
- 4: The golden era of antibiotics
- 5: Conclusion
- References
- Chapter 4: Challenges in the development of novel antibiotics
- Abstract
- 1: Introduction
- 2: Target product profiles for new antibacterials
- 3: Developing novel antibiotics
- 4: Case studies: Development of novel antibiotics
- 5: The role of public–private partnerships (PPPs) in developing new antibiotics
- 6: Conclusions
- References
- Section III: Antibiotics and therapeutics
- Chapter 5: Beta-lactam antibiotics
- Abstract
- Acknowledgments
- 1: Introduction
- 2: Beta-lactam antibiotics: Types, structure, and mechanism of action
- 3: Penicillins and cephalosporins: Discovery and biosynthetic pathways
- 4: Resistances: Mechanism and clinical relevance
- 5: Omics in the development of beta-lactams
- 6: Future outlook
- References
- Chapter 6: Aminoglycoside antibiotics
- Abstract
- 1: Introduction
- 2: Targeting RNA with AGAs
- 3: Aminoglycoside resistance
- 4: Toxicity
- 5: Pharmacokinetics and pharmacodynamics
- 6: Development of second-generation AGAs
- 7: Aminoglycoside-based biomaterials
- 8: Outlook and future perspectives
- References
- Chapter 7: Chloramphenicol and tetracycline (broad spectrum antibiotics)
- Abstract
- 1: Introduction
- 2: Tetracyclins
- 3: Mode of action of tetracyclines
- 4: Tetracycline resistance with mechanisms in biochemistry and genetics
- 5: Chloramphenicol
- 6: Structural-activity relationship
- 7: Chloramphenicol resistance
- 8: Combination effect of chloramphenicol with other antibiotics
- 9: Conclusion
- Further reading
- Chapter 8: Macrolide antibiotics
- Abstract
- 1: Introduction
- 2: The binding site of macrolide
- 3: Mode of action
- 4: Classification of macrolide antibiotics
- 5: Administration
- 6: Side effects
- 7: Contradictions
- 8: Monitoring
- 9: Toxicity
- 10: Resistance
- 11: Conclusion
- Further reading
- Chapter 9: Lincosamide and glycopeptide antibiotics
- Abstract
- 1: Introduction
- 2: Structures of lincosamides and glycopeptides antibiotics
- 3: Mechanism of action
- 4: Bacterial resistance
- 5: Semisynthetic glycopeptide antibiotics
- 6: Biological activity and medicinal importance
- 7: Conclusion
- References
- Chapter 10: Antimicrobial lipopeptides: Multifaceted designs to curb antimicrobial resistance
- Abstract
- 1: Introduction
- 2: Naturally occurring lipopeptide antimicrobials
- 3: Semisynthetic glycolipopeptides
- 4: Synthetically designed lipopeptide antimicrobials
- 5: Conclusion and future outlook
- References
- Chapter 11: Antifungal compounds: With special emphasis on echinocandins, polyenes, and heterocyclic benzofurans
- Abstract
- 1: Introduction
- 2: Polyenes
- 3: Echinocandins
- 4: Heterocyclic benzofurans
- 5: Conclusion
- References
- Further reading
- Chapter 12: Antibiotics in the management of tuberculosis and cancer
- Abstract
- 1: Introduction to antibiotics, tuberculosis, and cancer
- 2: Antibiotics in the management of tuberculosis
- 3: Antibiotics in the management of cancer
- 4: Recent advances in the antibiotics discovery for tuberculosis: Biotechnology perspectives
- 5: Recent advances in the antibiotics discovery for cancer: Biotechnology perspectives
- 6: Conclusion and future perspective
- References
- Further reading
- Section IV: Toxicity and antibiotic resistance
- Chapter 13: Toxicity consideration of antibiotics
- Abstract
- 1: Introduction
- 2: Mechanism of antibiotic toxicity
- 3: Risk factors influencing antibiotic toxicity
- 4: Common features of antibiotic toxicity
- 5: Consideration to avoid antibiotic toxicity
- 6: Conclusion
- References
- Chapter 14: Rational use of antibiotics—Save antibiotics for future generations
- Abstract
- Consent for publication
- Conflict of interest
- Acknowledgments
- 1: Introduction
- 2: Antimicrobial drug resistance overview
- 3: Global burden of antibiotics in different sectors
- 4: Cause of spread of antimicrobial drug resistance
- 5: Global impact of unsustainable management
- 6: Steps required for saving antibiotics for future generations
- 7: Currently active National Action Plans on AMR
- 8: Future prospects and conclusions
- References
- Chapter 15: Combined use of antibiotics
- Abstract
- 1: Introduction
- 2: Combination antibiotics therapy for multidrug-resistant bacteria
- 3: Combinations of antibiotics with Class Ia antibiotic adjuvants
- 4: Combined use of antibiotics with Class Ib adjuvants
- 5: Combined use of antibiotics with Class II adjuvants
- 6: Future perspectives
- References
- Chapter 16: Antibiotic resistance—A global crisis
- Abstract
- 1: Introduction
- 2: Antibiotic resistance
- 3: Causes of antibiotic resistance
- 4: Management of antibiotic resistance
- 5: Conclusion
- References
- Chapter 17: Traditional medicine in the management of microbial infections as antimicrobials: Pros and cons
- Abstract
- Acknowledgment
- 1: Introduction
- 2: Data synthesis
- 3: Mother nature: The pharmacopeia of the living kingdom
- 4: Role of TM in infection management
- 5: Traditional medicine on fungal infection
- 6: TM against viruses
- 7: TM in protozoal infections
- 8: Potential of TM-based future antimicrobials
- 9: Conclusion and future direction
- References
- Section V: Others
- Chapter 18: Quinolones as antimicrobial and antiresistance agents
- Abstract
- 1: An overview of quinolones and their structure-activity relationship
- 2: Pharmacology and clinical uses
- 3: Mode of action
- 4: Mode of resistance
- 5: Quinolone-topoisomerase interactions
- 6: The state of the art in the basic research for new quinolones
- 7: Modulation of resistance: NorA efflux pump and MRSA
- 8: Conclusion
- References
- Chapter 19: Herbal drugs as antibiotics
- Abstract
- Acknowledgments
- 1: Introduction
- 2: What is the need for herbal antibiotics?
- 3: Therapeutic effects of herbs
- 4: Herbs for their Antibiotic actions
- 5: Herbal drugs as antibiotics in respiratory ailments
- 6: Conclusion
- References
- Chapter 20: Challenges for use of antibiotics in pediatric and geriatric population
- Abstract
- 1: Introduction
- 2: Considerations
- 3: Absorption
- 4: Distribution
- 5: Metabolism
- 6: Elimination
- 7: Pharmacodynamics properties of antibiotics used in both pediatric and geriatric patients
- 8: Adverse drug reaction and adverse drug events
- 9: Antibiotic allergy
- 10: Medication errors
- 11: Off-label antibiotic usage
- 12: Parents’ role
- 13: Prescriber role
- 14: Discussion
- 15: Conclusion
- References
- Chapter 21: Role of antibiotics in hospital-acquired infections and community-acquired infections
- Abstract
- 1: Introduction
- 2: Antibiotics: The magic bullets
- 3: Which came first? Antibiotics or AMR?
- 4: Antimicrobial resistance: A global challenge
- 5: Colonization to infection: Understanding the basics
- 6: Hospital and community: Two different ecosystems
- 7: Hospital-acquired infections: An introduction
- 8: Community-acquired infections (CAI): An introduction
- 9: When not to use antibiotics?
- 10: Challenges in implementation of rational antibiotic use policies and practices in LMIC
- 11: Preventive strategies against antibiotic misuse
- 12: Conclusions
- References
- Chapter 22: Adult sepsis as an emerging hospital-acquired infection: Challenges and solutions
- Abstract
- 1: Introduction
- 2: Why is sepsis the most precarious HAI
- 3: Challenges in the diagnosis of sepsis
- 4: Treatment challenges
- 5: Clinical conditions compromising sepsis outcome
- 6: Tackling the challenges
- 7: Conclusion
- References
- Chapter 23: Probiotics: A solution to the prevention of antimicrobial resistance
- Abstract
- 1: Introduction
- 2: Mechanisms of probiotic action
- 3: Antimicrobial activity of probiotics
- 4: Modulation of immune responses
- 5: Conclusion
- References
- Chapter 24: Role of modern drug delivery in antibiotic therapy
- Abstract
- 1: Introduction
- 2: Nanotechnological approaches for antibiotic delivery
- 3: Stimuli-responsive antibiotic drug delivery
- 4: Localized implantable antibiotic drug-delivery
- 5: Conclusion
- References
- Chapter 25: Antibiotic residues in food
- Abstract
- 1: Introduction
- 2: Classes of antibiotics used in aquaculture (fish), agriculture (plant), poultry, and livestock (animal)
- 3: Laboratory testing of antibiotic residues
- 4: Antibiotic residues in food: Fish, plant, and animal foods
- 5: Health consequences of antibiotic residues
- 6: Management of antibiotic residues
- 7: Conclusion
- References
- Chapter 26: Clinical trials, regulatory considerations, and market overview of antibiotics
- Abstract
- 1: Introduction
- 2: Classification of antibiotics
- 3: The US regulator (Food and Drug Administration)
- 4: Different applications submitted at US-FDA
- 5: Antibacterial susceptibility test interpretive criteria of FDA
- 6: Role of clinical trials and FDA in antibiotic development
- 7: Natural product-based antibiotic discovery
- 8: Market overview of antibiotics
- 9: Conclusion
- References
- Index
- Edition: 1
- Published: July 13, 2023
- Imprint: Academic Press
- No. of pages: 550
- Language: English
- Paperback ISBN: 9780323953887
- eBook ISBN: 9780323957861
AD
Amal Kumar Dhara
Dr. Amal Kumar Dhara (MPharm, PhD) has over 20 years of teaching and research experience in the fields of Pharmacology and Toxicology, especially in the areas of neuropharmacology and anti-inflammatory, antiulcer, and free radical scavenging activities of indigenous Indian plants. He earned his PhD in Pharmaceutical Sciences from Jadavpur University, Kolkata, West Bengal, India. Currently, Dr. Dhara works as a Lecturer in Pharmacy (Associate Professor) at Contai Polytechnic, Purba Medinipur, West Bengal, India.
Affiliations and expertise
Department of Pharmacy, Contai Polytechnic, Government of West Bengal, Contai, Purba Medinipur, West Bengal, IndiaAN
Amit Kumar Nayak
Dr. Amit Kumar Nayak (MPharm, PhD) is working as a professor, at the Department of Pharmaceutics, School of Pharmaceutical Sciences, Siksha ‘O' Anusandhan (Deemed to be University), Odisha, India. He has earned his PhD from IFTM University, Moradabad, Uttar Pradesh, India. He has over 14 years of research experiences in the field of pharmaceutics, especially in the development and characterization of novel biopolymeric and nanostructured drug delivery systems. Till date, he has authored more than 138 research and review publications in various high-impact peer-reviewed journals and 135 book chapters. He has edited/authored 23 international books to his credit. Dr. Nayak has presented his research work at several conferences. He has received University Foundation Day Research Award, 2019 and 2022 by Biju Patnaik University of Technology, Odisha. Dr. Nayak is a life member of the Association of Pharmaceutical Teachers of India (APTI) and a registered pharmacist.
Affiliations and expertise
Professor, Department of Pharmaceutics, School of Pharmaceutical Sciences, Siksha 'O' Anusandhan (Deemed to be University), Bhubaneswar, Odisha, IndiaDC
Debprasad Chattopadhyay
Dr. Debprasad Chattopadhyay (PhD) has over 38 years of research experience in the field of Microbiology, Virology, Traditional Medicine, Ethnomedicine, and Molecular Medicine in identifying nature-based leads against difficult-to-treat diseases through documentation and validation of purity, safety, and potency (PSP) of traditional practices of Indian tribes with mode or molecular mechanism of action. He is currently the editor of the prestigious journal Frontiers in Pharmacology, editorial board member of the Journal of Ethnopharmacology, and reviewer of more than 40 peer-reviewed journals. He is the recipient of several awards such as Outstanding Ethnopharmacologist (2016), Best Science Communicator (2009), Amiya Bose Oration (2008), R.V. Rajam Endowment of IMA 1998, and International Society of Chemotherapy Young Scientist 1991.
Affiliations and expertise
School of Life Sciences, Swami Vivekananda University, Barrackpore, Kolkata, India ICMR-National Institute of Traditional Medicine, Nehru Nagar, Belagavi, IndiaRead Antibiotics - Therapeutic Spectrum and Limitations on ScienceDirect